|
Modi-1, anti-citrullinated neoepitope vaccine, alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal, and ovarian cancers: ModiFy phase I/II basket clinical trial—Report after completion of monotherapy dose-finding. |
|
Christian H.H Ottensmeier |
Stock and Other Ownership Interests - NEUVOGEN |
Honoraria - Delcath Systems; Transgene |
Consulting or Advisory Role - Bristol-Myers Squibb; Delcath Systems; Merck Sharp & Dohme; NEUVOGEN |
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme |
Research Funding - BioNTech (Inst); Bristol-Myers Squibb (Inst); Delcath Systems (Inst); Merck Sharp & Dohme (Inst); PsiOxus Therapeutics (Inst); Scancell (Inst); Touchlight Genetics (Inst); Verastem (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Delcath Systems |
Other Relationship - Transgene |
|
|
Honoraria - Avammune; Bristol-Myers Squibb; Da Volterra; Lift Biosciences; Mursla Bio; Roche/Genentech; Starpharma |
Consulting or Advisory Role - AstraZeneca; Da Volterra; EISAI; H3 Biomedicine; Ipsen; Mina Therapeutics; Roche |
Speakers' Bureau - Bayer; Falk Pharma; Roche; ViiV Healthcare |
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst) |
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; MSD Oncology |
Other Relationship - Wiley |
|
|
Stock and Other Ownership Interests - AstraZeneca (I) |
Consulting or Advisory Role - Gilead Sciences; MSD |
Research Funding - AstraZeneca/MedImmune (Inst) |
Travel, Accommodations, Expenses - Gilead Sciences; MSD Oncology; Novartis |
|
|
Consulting or Advisory Role - Bicycle Therapeutics (Inst); Boxer Capital (Inst); Bristol-Myers Squibb (Inst); Duke Street Bio (Inst); Eisai (Inst); Ellipses Pharma (Inst); Eugit Therapeutics (Inst); EUSA Pharma (Inst); MedAnnex (Inst); MSD (Inst); Pfizer/EMD Serono (Inst); Vaccitech (Inst) |
Speakers' Bureau - Bristol-Myers Squibb (Inst); Eisai (Inst); EUSA Pharma (Inst); Ipsen (Inst) |
Research Funding - BiolineRx (Inst); BioNTech (Inst); Boston Pharmaceuticals (Inst); Incyte (Inst); Medannex (Inst); Merck Sharp & Dohme (Inst); Nouscom (Inst); Nucana (Inst); Roche/Genentech (Inst); Sapience Therapeutics (Inst); Scancell (Inst); Sierra Oncology (Inst); Verastem (Inst) |
Travel, Accommodations, Expenses - BioNTech; Bristol-Myers Squibb; EUSA Pharma; Ipsen; MSD |
|
|
Speakers' Bureau - Britol Myers Squibb (Inst) |
Research Funding - Scancell (Inst) |
Travel, Accommodations, Expenses - EUSA Pharma |
|
|
Consulting or Advisory Role - Orion Biotechnology; Oxcia |
Research Funding - Amgen (Inst); AstraZeneca (Inst); MSD Oncology (Inst); Roche (Inst); Scancell Ltd. (Inst); Sun Pharma (Inst) |
|
|
Stock and Other Ownership Interests - AstraZeneca |
Travel, Accommodations, Expenses - Boehringer Ingelheim |
|
|
No Relationships to Disclose |
|
|
Employment - Clarity Pharmaceuticals; Hubro Therapeutics; Scancell Ltd. |
Stock and Other Ownership Interests - Hubro Therapeutics (Inst) |
Consulting or Advisory Role - Clarity Pharmaceuticals; Scancell Ltd. |
Travel, Accommodations, Expenses - Hubro Therapeutics; Scancell Ltd. |
|
|
Employment - Scancell Ltd. |
Stock and Other Ownership Interests - Scancell Ltd. |
Travel, Accommodations, Expenses - Allergy Therapeutics; Scancell Ltd. |
|
|
Employment - Scancell Ltd. |
Stock and Other Ownership Interests - Scancell Ltd. |
Travel, Accommodations, Expenses - Scancell Ltd. |
|
|
No Relationships to Disclose |